Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02337517 · ClinicalTrials.gov registry record · Phase 2

Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease

A Phase 2 study, sponsored by National Cancer Institute (NCI).

Terminated
Registry status
Phase 2
Development phase
6
Enrollment target

NCT02337517: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).

NCT02337517 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02337517, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).

TERMINATED
Registry status
Phase 2
Development phase
6 participants
Enrollment target

Study Summary

This pilot clinical trial studies how well vismodegib works in treating patients with chronic graft-versus-host disease that did not respond to previous steroid treatment. Chronic graft-versus-host disease can cause a build-up of scar tissue under the skin and lead to symptoms such as sclerodermatous skin changes, dry mouth, dry eye, narrowing of the esophagus, or vaginal graft-versus-host disease. Vismodegib may work against the build-up of scar tissue and be a better treatment for chronic graft-versus-host disease caused by a hematopoietic stem cell transplant.

Primary Outcome

Defined as the count of participants at six months with an absence of non relapse mortality (NRM), no recurrent malignancy, steroid dose at 6 months =\< 0.2 mg/kg/day of prednisone dose equivalent (PDE), and no addition of new systemic treatment for chronic graft-versus-host disease (GVHD) at six months after start of treatment.

Interventions

  • OTHER Laboratory Biomarker Analysis
  • DRUG Vismodegib

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2015-09-08
Est. Completion 2018-06-28
Phase Phase 2
National Cancer Institute (NCI)

3,257 total trials

Why NCT02337517 stopped before completion

NCT02337517 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).

The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT02337517 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02337517 about?

NCT02337517 is a clinical study titled "Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease". This pilot clinical trial studies how well vismodegib works in treating patients with chronic graft-versus-host disease that did not respond to previous steroid treatment. Chronic graft-versus-host disease can cause a build-up of scar tissue under the skin and lead to symptoms such as sclerodermatou...

What is the current status of trial NCT02337517?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2015-09-08. Estimated completion is 2018-06-28.

What interventions are being tested in trial NCT02337517?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Vismodegib (DRUG).

Who is sponsoring clinical trial NCT02337517?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Learn More About Clinical Trials

How this trial's enrollment target compares

Where NCT02337517's enrollment target sits among peer trials

6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02337517, the US trial registry maintained by the National Library of Medicine. NCT02337517 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.